West Boosts Dublin Facility to Support Injectable Therapies for Diabetes and Obesity
West Pharmaceutical Services opened a new 165,000 square foot building at its Damastown, Dublin site on March 31, 2026. The expansion aims to boost capacity for high-volume injectable drug manufacturing and handling. West boosts its Dublin facility to support injectable therapies for diabetes and obesity across global supply chains.
Facility upgrades and capabilities
The Damastown expansion adds advanced automation and commercial-scale drug-handling capabilities. It builds on existing component molding, device assembly, and packaging operations.
- 165,000 square feet of new space.
- Enhanced automation for manufacturing and assembly.
- Expanded capabilities for handling finished drug products.
Integrated contract services under West Vantage
The work at Damastown is part of West Vantage, the company’s contract services business. West Vantage provides end-to-end services from concept to regulatory support.
- Product conceptualization and development.
- Device manufacturing, assembly, and packaging.
- Validation, analytical testing, and regulatory assistance.
Leadership and local partners at the opening
Executives and officials attended the ribbon-cutting. Present were Eric Green, Chief Executive Officer of West, and Aileen Ruff-Patry, President of Contract Manufacturing.
Also attending were Jack Chambers, Ireland’s minister for public expenditure and infrastructure, and Michael Lohan, Chief Executive Officer of IDA Ireland.
Strategic importance
The site will increase West’s ability to support next-generation GLP-1 treatments. It aims to improve security of supply for injectable therapies worldwide.
Company leadership said the expansion will accelerate time to market for partners. The move reinforces West’s role as a contract manufacturing partner for pharmaceutical and biotech firms.
Company profile and scale
West is headquartered in Exton, Pennsylvania. The company employs more than 10,000 people at roughly 50 sites, including 25 manufacturing facilities worldwide.
West delivers over 41 billion components and devices annually. In fiscal 2025 the company reported $3.07 billion in net sales. West trades on the New York Stock Exchange under the symbol WST and is included in the S&P 500.
Filmogaz.com will follow developments as the Damastown site begins commercial operations supporting injectable therapies for diabetes and obesity.
